RA

Rahul Anam

Active Director Director DIN 10228352
DIN 10228352 First appointment Jul 2023 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Jul 2023
Shareholding value •••• Premium profile

About Rahul Anam

Data last updated:

Rahul Anam is a Director at Infyzer Pharmaceutical Private Limited (since 2023). The company operates in Pharma. Infyzer Pharmaceutical Private Limited reported revenue of ₹5,247 (FY 2024).

DIN 10228352
Primary Designation Director
Industry Pharma
First Appointment 06 Jul 2023
Oldest Company Age 3 yrs
Largest company Infyzer Pharmaceutical Private Limited · ₹5,247 (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director06 Jul 20232023₹5,247 (FY 2024)Active

Board colleagues of Rahul Anam

NameDINCompanyDesignation
Shazidur Rohman11189059Infyzer Pharmaceutical Private LimitedDirector

Directorship timeline

Open interactive timeline →
Infyzer Pharmaceutical Private Limited
Premium access

Shareholding and investment profile for Rahul Anam

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Rahul Anam

Rahul Anam currently holds 1 directorship: Infyzer Pharmaceutical Private Limited (Director, since 06 Jul 2023, revenue ₹5,247 (FY 2024)).

Rahul Anam was first appointed on 06 Jul 2023 as Director at Infyzer Pharmaceutical Private Limited.

The current boards of Rahul Anam's companies include Shazidur Rohman (Infyzer Pharmaceutical Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available